-+ 0.00%
-+ 0.00%
-+ 0.00%

AEOVIAN PHARMACEUTICALS RAISES $55 MILLION TO ADVANCE FIRST-IN-CLASS SELECTIVE MTORC1 INHIBITOR FOR TUBEROUS SCLEROSIS COMPLEX-RELATED EPILEPSY

路透·12/16/2025 13:00:58

登錄查看新聞詳情